{
    "ticker": "BBLU",
    "name": "Bluebird Bio, Inc.",
    "description": "Bluebird Bio, Inc. is a biotechnology company that focuses on developing gene therapies for genetic diseases and cancer. Founded in 1992 and headquartered in Cambridge, Massachusetts, Bluebird aims to transform the lives of patients with severe genetic disorders and cancer through innovative treatments based on its proprietary gene therapy technologies. The company is notable for its work in the field of lentiviral vector technology, which is used to deliver genes to patients' cells. Bluebird's lead product candidates include therapies for conditions such as sickle cell disease, beta-thalassemia, and various forms of cancer. The company is committed to advancing its clinical programs while maintaining a strong focus on patient safety and efficacy. With a robust pipeline of clinical trials, Bluebird Bio seeks to address unmet medical needs and improve the quality of life for patients worldwide. The company's mission is to provide transformative therapies that can change the course of diseases that have historically been difficult to treat.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "1992",
    "website": "https://www.bluebirdbio.com",
    "ceo": "Andrew Obenshain",
    "social_media": {
        "twitter": "https://twitter.com/bluebirdbio",
        "linkedin": "https://www.linkedin.com/company/bluebirdbio/"
    },
    "investor_relations": "https://ir.bluebirdbio.com",
    "key_executives": [
        {
            "name": "Andrew Obenshain",
            "position": "CEO"
        },
        {
            "name": "Nick Leschly",
            "position": "Co-Founder and Former CEO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "Zynteglo",
                "Skysona",
                "LentiGlobin"
            ]
        }
    ],
    "seo": {
        "meta_title": "Bluebird Bio, Inc. | Gene Therapies for Genetic Diseases",
        "meta_description": "Bluebird Bio, Inc. is a leader in gene therapy, dedicated to transforming the lives of patients with genetic diseases and cancer through innovative treatments.",
        "keywords": [
            "Bluebird Bio",
            "Gene Therapy",
            "Biotechnology",
            "Genetic Diseases",
            "Cancer Treatments"
        ]
    },
    "faq": [
        {
            "question": "What does Bluebird Bio specialize in?",
            "answer": "Bluebird Bio specializes in developing gene therapies for genetic diseases and cancer."
        },
        {
            "question": "Who is the CEO of Bluebird Bio?",
            "answer": "Andrew Obenshain is the CEO of Bluebird Bio, Inc."
        },
        {
            "question": "Where is Bluebird Bio headquartered?",
            "answer": "Bluebird Bio is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Bluebird Bio's main products?",
            "answer": "Bluebird Bio's main products include Zynteglo, Skysona, and LentiGlobin."
        },
        {
            "question": "When was Bluebird Bio founded?",
            "answer": "Bluebird Bio was founded in 1992."
        }
    ],
    "competitors": [
        "EDIT",
        "CRSP",
        "ALNY",
        "NVTA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "CELG",
        "REGN"
    ]
}